No Data
No Data
Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280
BofA Securities Maintains ResMed(RMD.US) With Buy Rating
Oppenheimer Maintains ResMed(RMD.US) With Hold Rating
Express News | RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $224
Bank of America Securities Sticks to Its Buy Rating for Resmed (RMD)
Needham Maintains ResMed(RMD.US) With Hold Rating
No Data
No Data